FIGURE 1: Therapeutic strategies to limit protein aggregation based disorders.

Many neurodegeneration disorders are characterized by increased protein aggregation of diseased associated proteins like α-synuclein and TDP-43. The yeast specific disaggregase Hsp104 and its variants (green) have been shown to be an effective in limiting inclusion formation and accumulation. Hsp104 acts on the inclusion to dissolve and restore them to the properly folded soluble form (TDP-43) as well as eliminate toxic soluble oligomeric forms (α-synuclein) of the protein. Additionally, caspase/metacaspase family of proteases (red) have also been shown to limit inclusion formation by directly cleaving the disease associated protein (TDP-43), which is subsequently degraded by the proteasome.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Please refer to our "privacy statement" and our "terms of use" for further information.

Close